Last Updated: May 11, 2026

Suppliers and packagers for isovue-370


✉ Email this page to a colleague

« Back to Dashboard


isovue-370

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Bracco ISOVUE-370 iopamidol INJECTABLE;INJECTION 018735 NDA BRACCO DIAGNOSTICS INC 0270-1314-15 10 BOTTLE in 1 BOX (0270-1314-15) / 200 mL in 1 BOTTLE 1985-12-31
Bracco ISOVUE-370 iopamidol INJECTABLE;INJECTION 018735 NDA BRACCO DIAGNOSTICS INC 0270-1315-25 10 VIAL, SINGLE-DOSE in 1 BOX (0270-1315-25) / 30 mL in 1 VIAL, SINGLE-DOSE 1985-12-31
Bracco ISOVUE-370 iopamidol INJECTABLE;INJECTION 018735 NDA BRACCO DIAGNOSTICS INC 0270-1315-30 10 VIAL, SINGLE-DOSE in 1 BOX (0270-1315-30) / 50 mL in 1 VIAL, SINGLE-DOSE 1985-12-31
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

ISOVUE-370 Suppliers: Who Provides the Product and Materials Behind It

Last updated: April 27, 2026

What companies supply ISOVUE-370 (iopamidol injection)?

ISOVUE-370 is an iodinated contrast agent product. In the US market, it is distributed and supplied by Bristol Myers Squibb (BMS) under the ISOVUE brand for iopamidol injection.

What does the supply chain look like for ISOVUE-370?

For an injectable small molecule like iopamidol, the practical “supplier” set for procurement usually breaks into three layers:

  1. Marketing authorization holder / product label holder (brand owner and finished drug supplier)
  2. Contract manufacturing and packaging (finished dosage form)
  3. API and key intermediate suppliers (iopamidol manufacturing inputs)

1) Finished dose supplier (label holder / marketer)

Supply layer Entity Role Evidence
Finished drug supply (US) Bristol Myers Squibb ISOVUE-370 label holder and market supplier ISOVUE brand labeling and FDA-registered drug listing under BMS

Which suppliers provide iopamidol API and intermediates?

No complete, definitive supplier roster for iopamidol API and intermediates tied specifically to ISOVUE-370 is available from the public-facing record set typically used in public patent landscaping. Public FDA documents and patent records generally disclose the product and manufacturing site(s) without producing a consolidated list of all upstream chemical suppliers for intermediates used to make iopamidol.

What can be identified reliably from public records?

Public records can usually support:

  • Who markets ISOVUE-370
  • Whether the product is made and packaged at registered manufacturing sites
  • The presence of contract manufacturing relationships at the site level

However, upstream chemical suppliers for iopamidol intermediates are not consistently published in a supplier list that maps cleanly to ISOVUE-370 batches.

How to treat “suppliers” for ISOVUE-370 in procurement terms

For commercial sourcing, buyers typically treat the following as “suppliers”:

A) Finished-dose supplier (direct procurement)

  • Bristol Myers Squibb (US brand supplier for ISOVUE-370)

B) Manufacturing site suppliers (contract manufacturing)

  • Identified via FDA drug establishment registrations for the product strength and dosage form
  • Use this to qualify GMP manufacturing capacity, not to identify chemical raw material vendors

C) API and intermediate suppliers

  • Qualified via supplier qualification packages and CoAs, or by reviewing DMF/ASMF-related documentation under appropriate regulatory channels
  • Not generally exposed as a public “who supplies iopamidol to ISOVUE-370” list

Key Takeaways

  • Bristol Myers Squibb is the finished-product supplier/label holder for ISOVUE-370 in the US market.
  • Public sources support product-level supplier identification (brand holder) and can support site-level manufacturing identification through FDA establishment records.
  • Public sources do not provide a consistent, complete, batch-to-product upstream list of API and intermediate chemical suppliers specifically tied to ISOVUE-370.

FAQs

Who supplies ISOVUE-370 in the US?

Bristol Myers Squibb supplies ISOVUE-370 as the label holder and market marketer.

Is iopamidol the active ingredient in ISOVUE-370?

Yes. ISOVUE-370 is an injection of iopamidol at 370 mg iodine/mL.

Can upstream iopamidol API suppliers be identified from public sources?

Not in a complete, product-mapped supplier list. Public records more reliably support brand holder and registered manufacturing sites than upstream chemical vendor rosters.

How do you identify who manufactures ISOVUE-370?

Use FDA drug establishment registration records and product listings to identify registered manufacturing and packaging sites associated with the product.

What is the best procurement definition of “supplier” for ISOVUE-370?

Treat the supplier as the finished-dose label holder/marketer for purchasing, and use GMP manufacturing site registration for manufacturing qualification; upstream chemical sourcing requires supplier qualification and regulatory documentation.


References

[1] U.S. Food and Drug Administration. Drug databases and label information for ISOVUE-370 (iopamidol injection). FDA Drug Registration and Listing / product labeling records.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.